WO1992002612A3 - Variants d'activateur de plasminogene tissulaire avec espacement reduit - Google Patents

Variants d'activateur de plasminogene tissulaire avec espacement reduit Download PDF

Info

Publication number
WO1992002612A3
WO1992002612A3 PCT/US1991/005418 US9105418W WO9202612A3 WO 1992002612 A3 WO1992002612 A3 WO 1992002612A3 US 9105418 W US9105418 W US 9105418W WO 9202612 A3 WO9202612 A3 WO 9202612A3
Authority
WO
WIPO (PCT)
Prior art keywords
variants
plasminogen activator
tissue plasminogen
decreased clearance
kringle
Prior art date
Application number
PCT/US1991/005418
Other languages
English (en)
Other versions
WO1992002612A2 (fr
Inventor
Bruce A Keyt
Mark J Zoller
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Priority to DE69113049T priority Critical patent/DE69113049T2/de
Priority to CA002086835A priority patent/CA2086835C/fr
Priority to EP91915181A priority patent/EP0542869B1/fr
Publication of WO1992002612A2 publication Critical patent/WO1992002612A2/fr
Publication of WO1992002612A3 publication Critical patent/WO1992002612A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6456—Plasminogen activators
    • C12N9/6459—Plasminogen activators t-plasminogen activator (3.4.21.68), i.e. tPA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne la préparation de variants d'activateur plasminogène tissulaire biologiquement actif (t-PA) avec espacement réduit par rapport à t-PA de type sauvage, y compris des variants qui ont une ou plusieurs altérations d'amino acide dans au moins le/ou les domaines kringle-1 et/ou kringle-2 de la molécule. Des séquences ADN peuvent être préparées, lesquelles codent les variants, ainsi que des vecteurs d'expression incorporant les séquences ADN et les cellules hôtes transformées avec les vecteurs d'expression. Les variants peuvent être utilisés dans des préparations pharmaceutiques pour traiter un état ou maladie vasculaire ou pour prévenir le dépôt ou la formation par adhésion ou reformation de fibrine chez les mammifères.
PCT/US1991/005418 1990-07-31 1991-07-30 Variants d'activateur de plasminogene tissulaire avec espacement reduit WO1992002612A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
DE69113049T DE69113049T2 (de) 1990-07-31 1991-07-30 Varianten des gewebeplasminogenaktivators mit vermindertem abbau.
CA002086835A CA2086835C (fr) 1990-07-31 1991-07-30 Variants d'activateur tissulaire du plasminogene a clairance reduite
EP91915181A EP0542869B1 (fr) 1990-07-31 1991-07-30 Variants d'activateur de plasminogene tissulaire avec espacement reduit

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US560,515 1983-12-12
US56051590A 1990-07-31 1990-07-31

Publications (2)

Publication Number Publication Date
WO1992002612A2 WO1992002612A2 (fr) 1992-02-20
WO1992002612A3 true WO1992002612A3 (fr) 1992-03-19

Family

ID=24238122

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1991/005418 WO1992002612A2 (fr) 1990-07-31 1991-07-30 Variants d'activateur de plasminogene tissulaire avec espacement reduit

Country Status (8)

Country Link
EP (1) EP0542869B1 (fr)
JP (1) JP3126381B2 (fr)
AT (1) ATE127839T1 (fr)
AU (1) AU645344B2 (fr)
CA (1) CA2086835C (fr)
DE (1) DE69113049T2 (fr)
DK (1) DK0542869T3 (fr)
WO (1) WO1992002612A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5156969A (en) * 1988-09-02 1992-10-20 Genentech Inc. Tissue plasminogen activator variant with deletion of amino acids 466-470 having fibrin specific properties
AU664469B2 (en) * 1992-06-03 1995-11-16 Genentech Inc. Tissue plasminogen activator glycosylation variants with improved therapeutic properties
US6355255B1 (en) 1998-12-07 2002-03-12 Regents Of The University Of Minnesota Streptococcal C5a peptidase vaccine
CN102203122A (zh) 2008-11-05 2011-09-28 惠氏有限责任公司 用于预防β-溶血链球菌(BHS)疾病的多组分免疫原性组合物

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0241208A1 (fr) * 1986-04-02 1987-10-14 Beecham Group Plc Enzyme fibrinolytique modifiée
WO1989004368A1 (fr) * 1987-11-06 1989-05-18 Genentech, Inc. Nouvelle variante d'activateurs de plasminogene de tissus humains

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH084501B2 (ja) * 1987-03-20 1996-01-24 エーザイ株式会社 糖鎖に関する変異ｔＰＡ
JPH03500002A (ja) * 1987-07-06 1991-01-10 ジェネティックス・インスチチュート・インコーポレーテッド 新規な血栓崩壊蛋白
IL90146A (en) * 1988-05-20 1994-10-07 Genentech Inc Glycosylation derivatives of tissue plasminogen activator
DE3825253A1 (de) * 1988-07-25 1990-02-01 Boehringer Mannheim Gmbh T-pa-derivat und seine herstellung

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0241208A1 (fr) * 1986-04-02 1987-10-14 Beecham Group Plc Enzyme fibrinolytique modifiée
WO1989004368A1 (fr) * 1987-11-06 1989-05-18 Genentech, Inc. Nouvelle variante d'activateurs de plasminogene de tissus humains

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
FASEB JOURNAL, vol. 4, no. 7, 26 April 1990, (Bethesda, US), M.J. ZOLLER et al.: "Mutational analysis and protein modeling of human tissue plasminogen activator (tPA)", page A1695, see abstract *
PATENT ABSTRACTS OF JAPAN, vol. 13, no. 24 (C-561)[3372], 19 January 1989, & JP,A,63230083 (EISAI CO., LTD) 26 September 1988, see abstract *
THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 226, no. 8, 15th March 1991, (Baltimore, MD, US), W.F. BENNETT et al.: "High resolution analysis of functional determinants on human tissue-type plasminogen activator", pages 5191-5201, see table 1 *
THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 265, no. 21, 25 July 1990, (Baltimore, MD, US), D. COLLEN et al.: "Biochemical and functional characterization of human tissue-type plasminogen activator variants with mutagenized kringle domains", pages 12184-12191, see the whole article *

Also Published As

Publication number Publication date
AU645344B2 (en) 1994-01-13
DE69113049D1 (de) 1995-10-19
DE69113049T2 (de) 1996-04-04
CA2086835A1 (fr) 1992-02-01
EP0542869A1 (fr) 1993-05-26
JPH05509229A (ja) 1993-12-22
CA2086835C (fr) 2002-04-02
ATE127839T1 (de) 1995-09-15
JP3126381B2 (ja) 2001-01-22
DK0542869T3 (da) 1996-02-05
EP0542869B1 (fr) 1995-09-13
AU8418791A (en) 1992-03-02
WO1992002612A2 (fr) 1992-02-20

Similar Documents

Publication Publication Date Title
AU4194689A (en) Tissue plasminogen activator having zymogenic or fibrin specific properties
GEP20012448B (en) Tissue Plasminogen Activators (Improved Variants)
MX9603925A (es) Combinaciones de anticoagulantes y proteinas activas tromboliticamente, y usos de las mismas.
AU3368497A (en) Human dnase i hyperactive variants
DE10199011I1 (de) Asp-B28-Insulinkristalle
US20140363394A1 (en) Formulation having mobilizing activity
EP1396542A3 (fr) Protéine de ligand de p-sélectine
WO1998000541A3 (fr) Procedes d'administration de porteurs fournissant des genes recombinants pour le traitement d'une maladie chez l'homme
WO1995030001A3 (fr) Nouvelle proteine ligand de p-selectine
ATE111525T1 (de) Plasminogenaktivator-varianten und verfahren zu ihrer herstellung.
WO1992002612A3 (fr) Variants d'activateur de plasminogene tissulaire avec espacement reduit
CA2075901A1 (fr) Activateur tissulaire du plasminogene specifique de la fibrine
WO1996021014A3 (fr) Production et administration de retrovirus recombines a titre eleve
CA2096851A1 (fr) Alleles activant le plasminogene des tissus
EP0431811A1 (fr) Agents thrombolytiques
CA2124937A1 (fr) Variantes de substitution du t-pa a specificite accrue a l'egard de la fibrine
EP0340933A3 (fr) Formules contenant de l'héparine
Buczko et al. Studies on the role of fibrinolysis and fibrinogen degradation products (FDP) in analgesic action of morphine
IE890270L (en) Proteins derived from human alpha 2 plasmin inhibitor

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IT LU NL SE

AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA JP US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IT LU NL SE

WWE Wipo information: entry into national phase

Ref document number: 2086835

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1991915181

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1991915181

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1991915181

Country of ref document: EP